The role of HRT in management of osteoporosis
1 March 2021
Twenty to thirty years ago, HRT was seen as the gold standard for both prevention and treatment of osteoporosis. Then, with publication of trials emphasising the risks of HRT and not balancing risks against the known benefits, it was less often considered as playing an important part in osteoporosis prevention or treatment, despite its proven significant benefits. In recent times however, the balance has swung back to recognising its importance in bone health, with a review published in Osteoporosis International confirming that HRT (referred to as MHT - Menopausal Hormone therapy) should be considered for maintaining bone health in women, in view of the robust data showing reduced fracture risk.
It seems that the tide has turned and that women can be confidently offered HRT not only for control of menopausal symptoms, but also for maintaining bone health and reducing risk of fracture. With one in two women now predicted to suffer from an osteoporotic fracture, it is essential that women are aware of the importance of bone health and of options that can help.
Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
S. Rozenberg, N. Al-Daghri, M. Aubertin-Leheudre, et al Osteoporos Int. 2020; 31(12): 2271-2286.
< Go Back
<< News Index